Jeremy D. Sherer

Widely recognized as a digital health thought leader, Jeremy Sherer counsels health care providers and suppliers, including hospital systems, national telehealth platforms, investors, and digital health startups on issues involving regulatory compliance, transactions, and innovative business arrangements.

Jeremy advises his clients on the full range of regulatory health care issues facing digital health stakeholders. Jeremy’s depth and breadth of experience enable him to help established and early-stage companies alike thoughtfully navigate a complex and ever-changing business and regulatory landscape. As one client’s CEO explained, “Jeremy is one of the best thought partners, and hands down the best legal navigator, I’ve found in the digital health space.”

Jeremy’s telehealth experience includes compliance with state licensure requirements for physicians and non-physician practitioners, corporate practice of medicine issues, remote prescribing (including controlled substances), patient consent, and Medicare, Medicaid, and commercial reimbursement. He also regularly advises clients on compliance with fraud and abuse laws, including federal and state anti-kickback and self-referral laws, as well as privacy issues arising under HIPAA and its state-level counterparts.

Jeremy has substantial experience pertaining to structuring, operationalizing, and scaling “Friendly PC” arrangements across all 50 states. He also advises venture capital and private equity firms conducting regulatory diligence associated with consequential investments in digital health and health care technology ventures, from seed stage funding to nine-figure raises.

Representative Matters

• Regularly guides digital health companies through building and scaling fifty-state “Friendly PC” arrangements.
• Guided academic medical center client through drafting and establishment of system-wide telehealth policies and procedures.
• Counseled national telebehavioral health platform on controlled substances prescribing to comply with the Ryan Haight Act and state law.
• Counseled nationally recognized health system on telehealth licensure waivers across all 50 states throughout the COVID-19 pandemic.
• Served as regulatory counsel to venture capital firm in successful $200 million investment in innovative telehealth platform’s Series D financing.
• Guided venture capital-backed pediatric care provider through successful $20 million series B as regulatory counsel, subsequent practice acquisitions to expand into additional states.
• Advised leading New England health system on federal and state telehealth controlled substances prescribing requirements throughout COVID-19 pandemic.
• Served as regulatory counsel to industry-leading artificial intelligence “symptom checker” solution, including structuring of “per-click” compensation arrangements to comply with applicable law and HHS-OIG guidance.
• Developed frameworks for publicly-traded telehealth platform client addressing non-physician practitioner supervision and proxy credentialing issues nationwide.
• Represented nationally recognized pediatric health system in establishing national telehealth practice, including advising on licensure, prescribing, consent, and corporate practice of medicine issues across all 50 states.
• Advise dozens of digital health companies on developing and implementing robust regulatory compliance programs addressing issues involving professional licensure, scope of practice, supervision, prescribing practices, and patient consent.